Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Rhea-AI Summary
Journey Medical (Nasdaq: DERM) will release its year-end 2025 financial results after market close on March 25, 2026.
The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET; registration is available online and the replay will remain available about 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – DERM
In the Mar 18 session, DERM declined 5.07%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Phase 1 results | Positive | -5.3% | Phase 1 Emrosi data showed no significant microbiome changes or safety issues. |
| Nov 12 | Q3 2025 earnings | Positive | -15.3% | Q3 2025 revenue grew 21% with improved margins and narrower net loss. |
| Nov 05 | Earnings date notice | Neutral | -1.8% | Announcement of timing and access details for Q3 2025 results call. |
| Oct 24 | Phase 3 efficacy data | Positive | -0.5% | Pooled Phase 3 Emrosi data showed higher IGA success and lesion reduction. |
| Oct 08 | Investor conferences | Neutral | -0.4% | Planned participation in October 2025 investor conferences and meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and earnings updates have often seen negative next‑day price reactions, suggesting a pattern of selling into good news.
Over the last several months, Journey Medical reported multiple milestones. On Nov 12, 2025, Q3 2025 results showed 21% year-over-year revenue growth to about $17.6M, improving gross margin and narrower net loss, yet the stock fell the next day. Clinical updates for Emrosi, including pooled Phase 3 efficacy data on Oct 24, 2025 and a Phase 1 microbiome study publication on Dec 10, 2025, also coincided with modest share price declines. The current year‑end 2025 earnings date notice fits this cadence of frequent clinical and financial communications.
Key Terms
u.s. food and drug administration regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET
SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10206557/103495af641. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
